Logo image of VRDN

VIRIDIAN THERAPEUTICS INC (VRDN) Stock Fundamental Analysis

NASDAQ:VRDN - Nasdaq - US92790C1045 - Common Stock - Currency: USD

16.84  +0.58 (+3.57%)

Fundamental Rating

3

VRDN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While VRDN seems to be doing ok healthwise, there are quite some concerns on its profitability. VRDN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRDN had negative earnings in the past year.
VRDN had a negative operating cash flow in the past year.
In the past 5 years VRDN always reported negative net income.
VRDN had a negative operating cash flow in each of the past 5 years.
VRDN Yearly Net Income VS EBIT VS OCF VS FCFVRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -46.65%, VRDN is in line with its industry, outperforming 51.43% of the companies in the same industry.
Looking at the Return On Equity, with a value of -51.01%, VRDN is in the better half of the industry, outperforming 65.05% of the companies in the same industry.
Industry RankSector Rank
ROA -46.65%
ROE -51.01%
ROIC N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
VRDN Yearly ROA, ROE, ROICVRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRDN Yearly Profit, Operating, Gross MarginsVRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VRDN has been increased compared to 1 year ago.
The number of shares outstanding for VRDN has been increased compared to 5 years ago.
VRDN has a better debt/assets ratio than last year.
VRDN Yearly Shares OutstandingVRDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRDN Yearly Total Debt VS Total AssetsVRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 11.37 indicates that VRDN is not in any danger for bankruptcy at the moment.
The Altman-Z score of VRDN (11.37) is better than 88.53% of its industry peers.
VRDN has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
VRDN has a worse Debt to Equity ratio (0.03) than 60.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 11.37
ROIC/WACCN/A
WACC9.7%
VRDN Yearly LT Debt VS Equity VS FCFVRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

VRDN has a Current Ratio of 19.49. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
VRDN has a Current ratio of 19.49. This is amongst the best in the industry. VRDN outperforms 93.01% of its industry peers.
VRDN has a Quick Ratio of 19.49. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
VRDN has a Quick ratio of 19.49. This is amongst the best in the industry. VRDN outperforms 93.01% of its industry peers.
Industry RankSector Rank
Current Ratio 19.49
Quick Ratio 19.49
VRDN Yearly Current Assets VS Current LiabilitesVRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

VRDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.22%, which is quite good.
The Revenue has been growing slightly by 6.34% in the past year.
Measured over the past years, VRDN shows a very negative growth in Revenue. The Revenue has been decreasing by -41.64% on average per year.
EPS 1Y (TTM)10.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.13%
Revenue 1Y (TTM)6.34%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%0%

3.2 Future

Based on estimates for the next years, VRDN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.75% on average per year.
The Revenue is expected to grow by 400.57% on average over the next years. This is a very strong growth
EPS Next Y-1.81%
EPS Next 2Y1.01%
EPS Next 3Y13.73%
EPS Next 5Y24.75%
Revenue Next Year-37.17%
Revenue Next 2Y939.66%
Revenue Next 3Y815.75%
Revenue Next 5Y400.57%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRDN Yearly Revenue VS EstimatesVRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
VRDN Yearly EPS VS EstimatesVRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRDN Price Earnings VS Forward Price EarningsVRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRDN Per share dataVRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as VRDN's earnings are expected to grow with 13.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.01%
EPS Next 3Y13.73%

More info and screens

0

5. Dividend

5.1 Amount

VRDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (7/16/2025, 12:00:42 PM)

16.84

+0.58 (+3.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-06 2025-08-06/amc
Inst Owners113.37%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.39B
Analysts85.22
Price Target40.16 (138.48%)
Short Float %13.22%
Short Ratio13.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.55%
Min EPS beat(2)5.31%
Max EPS beat(2)11.8%
EPS beat(4)2
Avg EPS beat(4)-0.51%
Min EPS beat(4)-12.54%
Max EPS beat(4)11.8%
EPS beat(8)5
Avg EPS beat(8)1.91%
EPS beat(12)6
Avg EPS beat(12)-7.46%
EPS beat(16)8
Avg EPS beat(16)-9.31%
Revenue beat(2)2
Avg Revenue beat(2)29.64%
Min Revenue beat(2)0.65%
Max Revenue beat(2)58.63%
Revenue beat(4)3
Avg Revenue beat(4)31.36%
Min Revenue beat(4)-18.06%
Max Revenue beat(4)84.21%
Revenue beat(8)3
Avg Revenue beat(8)-4.34%
Revenue beat(12)5
Avg Revenue beat(12)13.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.8%
EPS NY rev (1m)0.2%
EPS NY rev (3m)1.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-37.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4591.41
P/FCF N/A
P/OCF N/A
P/B 2.29
P/tB 2.29
EV/EBITDA N/A
EPS(TTM)-4.04
EYN/A
EPS(NY)-3.88
Fwd EYN/A
FCF(TTM)-3.4
FCFYN/A
OCF(TTM)-3.4
OCFYN/A
SpS0
BVpS7.34
TBVpS7.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.65%
ROE -51.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 116.6%
Cap/Sales 197.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.49
Quick Ratio 19.49
Altman-Z 11.37
F-Score3
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)191.45%
Cap/Depr(5y)174.87%
Cap/Sales(3y)166.8%
Cap/Sales(5y)103.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.13%
EPS Next Y-1.81%
EPS Next 2Y1.01%
EPS Next 3Y13.73%
EPS Next 5Y24.75%
Revenue 1Y (TTM)6.34%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%0%
Revenue Next Year-37.17%
Revenue Next 2Y939.66%
Revenue Next 3Y815.75%
Revenue Next 5Y400.57%
EBIT growth 1Y-41.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.93%
EBIT Next 3Y11.83%
EBIT Next 5Y41.25%
FCF growth 1Y-106.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-107.57%
OCF growth 3YN/A
OCF growth 5YN/A